drugset / Trial / NCT02165566

Humalog or Humulin for Intensive Insulin Therapy in Intensive Care Unit

NCT02165566

Phase 4 Completed 28 enrolled University of Roma La Sapienza
RandomizedCrossoverOpen-labelTreatment

Summary

Insulin preparation -random assignment to regular insulin lin or lispro insulin as first treatment- was administered at constant infusion rate (0.04 units/Kg/h) in patients presenting blood glucose concentration ≥180 mg/dl and was discontinued when blood glucose concentration ≤140 mg/dl (therapeutic blood glucose concentration drop). Further reduction in blood glucose concentration after discontinuation of insulin infusion was recorded (post-infusional blood glucose concentration drop). During the study period blood glucose concentration, in whole blood, was measured every 30 minutes. At least 6 hours interval was allowed between the 2 treatments.

Timeline

Start
2013-03
Primary completion
2014-03
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 0.04 iu/kg Other
Subject Insulin Lispro Protein / enzyme biologic 0.04 iu/kg Other

Indications